NHS Dudley Health Economy Medicines Formulary
Home > 8 Malignant disease and immunosuppression > 8.1 Cytotoxic drugs > 8.1.5 Other antineoplastic drugs > Gastric cancer (HER2-positive metastatic) - trastuzumab - NICE TAG TA208

Gastric cancer (HER2-positive metastatic) - trastuzumab - NICE TAG TA208

1.1 Trastuzumab, in combination with cisplatin and capecitabine or 5-fluorouracil, is recommended as an option for the treatment of people with human epidermal growth factor receptor 2 (HER2)-positive metastatic adenocarcinoma of the stomach or gastro-oesophageal junction who:

  • have not received prior treatment for their metastatic disease and

  • have tumours expressing high levels of HER2 as defined by a positive immunohistochemistry score of 3 (IHC3 positive).

1.2 People who are currently receiving treatment with trastuzumab for HER2-positive metastatic gastric cancer who do not meet the criteria in 1.1 should have the option to continue treatment until they and their clinicians consider it appropriate to stop.

https://www.nice.org.uk/guidance/TA208

Site by Devopa
© Copyright 2019 NHS. All rights reserved.